Press release
20 November, 2007

**Kringle Pharma Forms Business Alliance with Nippon Zenyaku Kogyo Co., Ltd. to Accelerate Commercialization of HGF for Animal Drugs.**

Kringle Pharma, Inc. (Head office located in Toyonaka, Osaka; President & CEO: Kunio Iwatani, “KRINGLE”) proudly announces that it has established a business alliance with Nippon Zenyaku Kogyo, Co., Ltd. (Head office located in Koriyama, Fukushima; President & Representative Director: Kuniaki Fukui, “ZENOAQ”), a leading company in the field of animal health products, to accelerate the commercialization of animal HGF (Hepatocyte Growth Factor) for animal drug application.

KRINGLE and ZENOAQ previously entered into two contracts in December of 2004; the Collaborative Research Agreement and the Licensing Agreement (collectively referred to as “2004 Agreements”) to develop animal-derived HGF for animal renal disease therapy.

KRINGLE and ZENOAQ have recently decided to continue this collaboration, expanding the applicable indications to other animal diseases in addition to renal disease. As part of the alliance, KRINGLE and ZENOAQ agreed to renew the 2004 Agreements and will be concluding the Renewed Collaborative Research Agreement and the Renewed Licensing Agreement (collectively referred to as “Renewed Agreements”). Moreover, ZENOAQ has decided to make a capital investment in KRINGLE with the intention of building a firmer relationship with KRINGLE.

Under the Renewed Agreements, KRINGLE will exclusively license out the relevant HGF patents and applications, for animal use only, needed to commercialize HGF-based animal drugs for renal disease and other indications. KRINGLE will also grant ZENOAQ exclusive rights to use KRINGLE’s proprietary know-how and information on HGF with a limitation to animal use. In addition, KRINGLE will also jointly work with ZENOAQ to establish a commercial production system to produce recombinant animal HGF protein.

Kunio Iwatani stated: “I am extremely proud that ZENOAQ, the leading company in the field of animal health products, has entered into a business partnership with our company. The alliance includes ZENOAQ’s capital investment in KRINGLE, by which means an even closer relationship between the companies will be forged. I am confident that this alliance will accelerate the development of HGF-based animal drugs”.

“I foresee a bright future arising from this alliance with KRINGLE”, declared Kuniaki Fukui. “KRINGLE is a global leader in recombinant HGF protein research and development. There is no doubt that the synergy created by combining KRINGLE’s highly sophisticated technology and ZENOAQ’s outstanding developmental capability in animal drugs, will lead to the development of HGF for animal medications being taken to the next level”.

About Kringle Pharma, Inc.
Kringle Pharma is a venture biopharmaceutical company spun-off from Osaka University. The company was established in 2001 to develop novel biopharmaceuticals based on HGF and NK4, both discovered by Professor Toshikazu Nakamura and Associate Professor Kunio Matsumoto at Osaka University (Dr. Matsumoto has been serving as a Professor at Kanazawa University since April 2007). HGF is considered as an intrinsic factor with an organotrophic role in the repair and regeneration of various tissues and organs, and is thought to have significant potential in becoming a regenerative medicine. NK4 is a molecule which functions as both an HGF-antagonist and an angiogenesis inhibitor that is induced by various growth factors including HGF. NK4 is a bi-functional and multi-target compound developed by Kringle Pharma for the treatment of various kinds of cancer.

For more details on Kringle’s technologies, please refer to the company’s website at www.kringle-pharma.com/en/index.html

About Nippon Zenyaku Kogyo, Co., Ltd.
ZENOAQ, the corporate brand of Nippon Zenyaku Kogyo Co., Ltd., is Japan's top company in the field of animal health products, running an integrated operation encompassing the development, production, import and sales of products enhancing animal health. Zenoaq has a production system complied with GMP standards, a research and development system with GLP standards, a quality control of the products with GQP standards, and a post-marketing assurance system with GVP standards. Moreover, Zenoaq is unique in the business in having 41 sales outlets throughout Japan. Zenoaq is making positive efforts toward forming a cooperative relationship with the very best companies in the field, both domestically and abroad, and has formed solid partnerships with many. Zenoaq boasts approximately 400 product lines to meet any kind of health care needs for animals, whether it be for food animals such as cattle, pigs and fowls or for companion animals such as dogs and cats.

For more details on Nippon Zenyaku Kogyo, Co., Ltd., please refer to the company’s website at www.zenoaq.jp/index2e.shtml

For more information, please contact:

Kiichi Adachi
EVP, Director of Business Development
Kringle Pharma, Inc.
Tel: +81 6 6831 3330
E-mail: info@kringle-pharma.com

Yasuyuki Suzuta
Chief Expert, Development Division, Research and Development Business Unit
Nippon Zenyaku Kogyo, Co., Ltd.
Tel: + 81 24 945 2300
E-mail: info@zenoaq.jp